An observational study in COPD and AE COPD, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre — 2 open to participants now, 2 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · McGill University Health Centre/Research Institute of the McGill University Health Centre.
Among the 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is one of 4 that started in 2025, is one of 6 observational ones, and was the 13th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 1 country. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 40+
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 2 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 35 across the 8 interventional studies, 44 across the 6 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is aimed to collect real-time physiological data using two wearable devices (a biometric ring and a biometric wristband), daily lung mechanical measurements by a handheld oscillometer, and participant-reported symptoms in patients with COPD remotely from their home environment. The data will be used to train and validate artificial intelligence and machine learning (AI/ML) models to predict COPD exacerbations in advance of their actual occurrence. The data will also be used to test the new severity classification system for exacerbations of COPD, as well as to determine important relationships between physiological measurements from the wearable devices, the handheld oscillometer, the self-reported symptoms, and the tests performed at the baseline visit.
A single-site, prospective, observational cohort study to collect high-quality multidimensional data from the wearable/portable devices, as well as symptom and exacerbation data, in high-risk patients with frequent exacerbations in order to develop a COPD exacerbation predictive model.
Patients with COPD with a documented history of frequent exacerbations.
While there is no specific method to estimate sample sizes for machine learning-based clinical research, based on two prior COPD studies measuring respiratory rate (RR) differences between stable-state and peak exacerbation phases, it was estimated that detecting a 4 breaths/min difference in RR (effect size 0.74) requires 17 prospectively collected exacerbation events, with alpha set to 0.05, power set to 0.8, and two-tailed analysis. Detecting a more subtle difference (i.e. 2 breaths/min; effect size 0.36) would require 63 events.
Assuming each participant experiences two exacerbations annually, 32 participants would meet these requirements. To account for the long observation period, the potential for non-events, and a 25% attrition rate, up to 50 participants will be recruited for this one-year study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this study, participants will be equipped with biometric wearable devices, i.e. ring and wristband, as well as with a handheld oscillometer, to measure their physiological parameters and lung mechanical changes (lung function).
Respiration
Respiratory rate (RR) and respiratory rate variability (RRV) measured with wearable devices
Time frame: Daily/nightly for 12 months
Cardiovascular
Heart rate (HR) and HR variability (HRV) measured with wearable devices
Time frame: Daily/nightly for 12 months
Oxygen level
Blood oxygen saturation (SpO2) measured with wearable devices
Time frame: Daily/nightly for 12 months
Step count
Parameter measured with wearable devices, related to activity.
Time frame: Daily/nightly for 12 months
Sleep duration
Parameter measured with wearable devices.
Time frame: Nightly for 12 months
Rapid eye movement (REM) sleep
Parameter measured with wearable devices.
Time frame: Nightly for 12 months
Deep sleep
Parameter measured with wearable devices.
Time frame: Nightly for 12 months
Body temperature
Peripheral body temperature measured with wearable devices
Time frame: Nightly for 12 months
Resistance at 5 Hz (R5)
Parameter measured at 5 Hz frequency with handheld oscillometry, related to lung mechanics/function.
Time frame: Daily for 12 months
Reactance at 5 Hz (X5)
Parameter measured at 5 Hz frequency with handheld oscillometry, related to lung mechanics/function.
Time frame: Daily for 12 months
Intra-breath difference between expiratory and inspiratory reactance (ΔXrs)
Parameter measured with handheld oscillometry, related to lung mechanics/function.
Time frame: Daily for 12 months
Tidal volume (Vt)
Parameter measured with handheld oscillometry, related to lung mechanics/function.
Time frame: Daily for 12 months
Respiratory flows
Inspiratory and expiratory flows measured with handheld oscillometry, related to lung mechanics/function.
Time frame: Daily for 12 months
Respiratory rate (RR)
Parameter measured with handheld oscillometry.
Time frame: Daily for 12 months
Minute ventilation (Ve)
Parameter measured with handheld oscillometry, related to lung mechanics/function.
Time frame: Daily for 12 months
Heart rate (HR) prior oscillometry test
Parameter measured with handheld oscillometry before performing oscillometry test.
Time frame: Daily for 12 months
Blood oxygen saturation (SpO2) prior oscillometry test
Parameter measured with handheld oscillometry before performing oscillometry test.
Time frame: Daily for 12 months
Daily symptom questionnaire
• Visual analog scale (VAS) scores for dyspnea, sputum volume, sputum purulence, cough, wheeze, and fatigue, scaled 0-10. Higher scores indicate worse symptoms.
Time frame: Daily for 12 months
Weekly exacerbation questionnaire
• Self report on any exacerbation(s) which occurred in the preceding week and their date(s), whether/how the exacerbation was treated, and in what treatment setting.
Time frame: Weekly for 12 months
Calories
Parameter measured with wearable devices, related to activity.
Time frame: Daily/nightly for 12 months
Metabolic equivalents
Parameter measured with wearable devices, related to activity.
Time frame: Daily/nightly for 12 months
Movement intensity
Parameter measured with wearable devices, related to activity.
Time frame: Daily/nightly for 12 months
Sleep efficiency
Parameter measured with wearable devices.
Time frame: Nightly for 12 months
Sleep oncet
Parameter measured with wearable devices.
Time frame: Nightly for 12 months
Sleep disturbance
Parameter measured with wearable devices.
Time frame: Nightly for 12 months
COPD Assessment Test (CAT)
Validated COPD questionnaire consisting of 8 questions and scaled 0-40. Higher scores indicate the severity of disease impact.
Time frame: Once (baseline visit)
6-Minute Walk Test (6MWT)
Standard and validated assessment in COPD. Outcomes include distance walked as well as heart rate (HR), oxygen saturation (SpO2), and respiratory rate (RR) during the test. the 6MWT will be performed once at baseline while the participant is wearing the biometric wearable devices.
Time frame: Once (baseline visit)
System Usability Scale (SUS)
Practical and reliable tool to determine the user experience with a variety of systems and devices. Scaled from 1-5, higher scores indicate better experience.
Time frame: Through study completion, 1 year.
Plan to share: No — Due to data privacy regulations, individual participant data collected during this study is not publicly accessible. However, access to anonymized data may be granted upon evaluation by the trial management group. Additional documents will also be available upon inquiry. All requests should be directed to the corresponding author (BAR).
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for May 2026, 12 months after the start.
Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 12 months is below that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
McGill University Health Centre/Research Institute of the McGill University Health Centre →